SOLVE FSHD Announces $3 Million Investment in Armatus Bio to Advance Gene Therapy Program for FSHD
VANCOUVER, British Columbia & COLUMBUS, Ohio--(BUSINESS WIRE)--SOLVE FSHD, a venture philanthropy organization committed to accelerating therapies for facioscapulohumeral muscular dystrophy (FSHD), today announced a $3 million investment in Armatus Bio, a biotechnology company developing next-generation vectorized RNAi therapeutics for neuromuscular diseases. The investment will support ARM-201, Armatus Bio's AAV-delivered microRNA therapy designed to silence the expression of DUX4, the toxic protein responsible for muscle degeneration in individuals with FSHD.
The investment is part of SOLVE FSHD's growing portfolio of therapeutic programs aimed at addressing FSHD through a range of innovative approaches.
The investment is part of SOLVE FSHD's growing portfolio of therapeutic programs aimed at addressing FSHD through a range of innovative approaches. ARM-201 is a potential best-in-class, single-dose therapeutic for the treatment of FSHD. Its proprietary miRNA payload is designed to reduce DUX4 expression and thereby arrest muscle weakening and atrophy, prevent further degeneration, and reduce inflammation and oxidative stress associated with the disease.
ARM-201 incorporates AAV-SLB101, a next-generation AAV capsid licensed from Solid Biosciences, which was rationally designed to target integrin receptors and has shown enhanced skeletal and cardiac muscle transduction, with decreased liver exposure in preclinical studies. It has also been shown to be well tolerated with robust transduction and expression levels seen in a clinical trial for Duchenne muscular dystrophy. With a pre-IND meeting successfully completed with the FDA, Armatus Bio will deploy SOLVE FSHD's investment towards critical IND-enabling activities, positioning ARM-201 for regulatory submission and entry into FSHD clinical trials.
'We're thrilled to support Armatus Bio in advancing a differentiated therapeutic approach that directly targets the genetic cause of FSHD,' said Eva Chin, PhD, Executive Director of SOLVE FSHD. 'This program represents an important step toward delivering meaningful treatments to the FSHD community. We believe Armatus has a strong scientific foundation, experienced leadership, and a focused development strategy that position them well for clinical and commercial success.'
'SOLVE FSHD's focused commitment to advancing therapeutic development for FSHD, combined with their collaborative approach and scientific expertise, has made them an invaluable partner for Armatus,' said Rachel Salzman, DVM, CEO of Armatus Bio. 'This investment provides critical resources to advance ARM-201 toward the clinic and positions us for continued growth as a company. We're excited to take this next step together and accelerate the path toward a much-needed therapy for the FSHD community.'
FSHD is one of the most common forms of muscular dystrophy, affecting approximately 1 in 8,000 individuals globally. With no approved treatments available, advancing promising therapies is critical to meeting the urgent needs of the FSHD community.
About SOLVE FSHD
SOLVE FSHD is a venture philanthropic organization established to catalyze innovation and accelerate key research in finding a cure for FSHD. Established by renowned Canadian entrepreneur and philanthropist, Chip Wilson, widely known as the founder and part owner of various technical apparel companies including lululemon and Amer Sports. The Wilson family has committed $100 million to kick-start funding into projects that support the organization's mission to solve FSHD by 2027. The goal of SOLVE FSHD is to find a solution that can slow down or stop muscle degeneration, increase muscle regeneration and strength, and improve the quality of life for those living with FSHD.
About Armatus Bio
Armatus Bio is a privately held late preclinical stage biotechnology company leveraging vectorized RNAi to address urgent unmet medical needs in genetically-driven neurological diseases. Based in Columbus, Ohio, the company is led by a seasoned team with expertise in drug development and delivery, and partnered with world renowned experts in vector biology, genomics, and neurology. In addition to ARM-201, Armatus is building a pipeline of precision medicines that can transform care for people with other genetic neuromuscular disorders.
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
6 hours ago
- Yahoo
Nintendo Switch 2 official specs confirm GPU similar to a mobile RTX 2050
When you buy through links on our articles, Future and its syndication partners may earn a commission. Leaked hardware specifications of the upcoming Nintendo Switch 2 have been circulating for a while, but we now have official confirmation of the new console's specs. Digital Foundry has claims it has officially confirmed that the Switch 2 will feature a custom Nvidia SoC with an Ampere-based GPU, 12GB of memory, and 256GB of CPU portion of the custom SoC sports eight ARM Cortex A78C cores, featuring the ARMv8 64-bit instruction set and cryptography extensions. Feeding the cores are four cache layers: a 64KB L1 instruction cache, a 64KB L1 data cache, 256KB of L2 cache per core, and 4MB of L3 cache that is shared among all eight cores. Digital Foundry clarified that six of the CPU cores will be available for games, while two will be strictly reserved for the operating system. This isn't new; it's a method used in the current Switch as well as in other modern consoles, such as the PS5. The CPU has an official maximum clock speed of 1.7 GHz; however, for the Switch 2, the developers have opted to run the CPU at a significantly lower speed: 1.1 GHz in "portable" mode and 0.998 GHz in "docked" mode. (That is not a typo; the CPU operates at a lower clock speed when docked, for unknown reasons.)The GPU portion of the SoC is based on Nvidia's two-generation-old Ampere architecture and sports 1,536 CUDA cores. The physical chip itself is rated for up to 1,400 MHz, but — similar to the CPU — Nintendo has opted to run the chip at significantly lower speeds on the Switch 2. In "portable" mode, the chip will operate at 561 MHz, and in "docked" mode, 1,007 MHz. The Switch 2's Ampere GPU resembles Nvidia's RTX 3050 and RTX 2050 mobile GPUs (the latter of which is also Ampere-based). Compared to these GPUs, the Switch 2's counterpart has 512 fewer CUDA cores (2,048 vs 1,536) and runs at significantly lower clock Ampere to the Switch 2 will give the console real-time ray-tracing capabilities and DLSS support. Nintendo has not announced any games with real-time ray-tracing capabilities, but Digital Foundry and other outlets have demonstrated that it is possible on the RTX 2050 mobile. By contrast, several games have been confirmed to be coming with DLSS support, with Cyberpunk 2077 in particular offering variable real-time resolution scaling with DLSS (a feature of DLSS that is exceptionally rare to see, even on PC).The memory subsystem is powered by two 6GB LPDDR5X memory modules (12GB total) operating on a 128-bit memory interface. The chips themselves operate at 2,133 MHz in "portable" mode and 3,200 MHz in "docked" mode. This translates to 68 GB/s of memory bandwidth in "portable" mode (2,133 MHz) and 102 GB/s of bandwidth in "docked" mode (3,200 MHz). 9GB of memory capacity is available for games to take advantage of, while the remaining 3GB is reserved strictly for the OS. Storage consists of 256GB of internal UFS-based storage and a microSD Express card slot capable of supporting cards with up to 2TB capacity. To speed up storage decompression, the custom Nvidia SoC sports a dedicated decompression block dedicated to decompressing data from the Switch 2's SSD (and/or SD slot) into memory. The Switch 2's compression block supports the LZ4 format that is built into Nintendo's NSP Nintendo Switch 2 is the successor to the original Switch, which debuted all the way back in 2017. The new variant will arrive on June 5, 2025, for $ Tom's Hardware on Google News to get our up-to-date news, analysis, and reviews in your feeds. Make sure to click the Follow button.
Yahoo
2 days ago
- Yahoo
H.C. Wainwright Reiterates Buy Rating on Immix Biopharma (IMMX) Following Promising Interim Results from NXC-201 Trial
On June 4, analyst Robert Burns of H.C. Wainwright reiterated a Buy rating on Immix Biopharma, Inc. (NASDAQ:IMMX) with a price target of $7.00. The analyst based the rating on the promising interim results from the NEXICART-2 Phase 1/2 clinical trial of NXC-201, presented at the 2025 American Society of Clinical Oncology Annual Meeting (ASCO 2025) in Chicago, Illinois. The trial assessed the efficacy of NXC-201 in patients with relapsed/refractory AL amyloidosis and delivered a 100% response rate, with a considerable portion attaining a complete hematologic response. The analyst reasoned that the absence of hematologic relapse or progression and the rapid mean time to response further highlight NXC-201's potential as a viable treatment. A doctor in a white coat discussing clinical trial results with a patient in an oncology practice. Burns also reasoned that NXC-201 appears to have a favorable safety profile, as no patients experienced severe cytokine release syndrome or neurotoxicity. While he highlighted the need for longer-term follow-up and the small sample size, the analyst stated that the interim results are promising when compared to existing treatments. This condition does not have FDA-approved agents, and there exists a fragmented treatment landscape post-frontline therapy, factors that suggest the notable market opportunity for NXC-201 and support the buy rating for Immix Biopharma, Inc. (NASDAQ:IMMX). Immix Biopharma, Inc. (NASDAQ:IMMX) is a biopharmaceutical company that develops therapies for inflammatory diseases and cancer. While we acknowledge the potential of IMMX as an investment, our conviction lies in the belief that some AI stocks hold greater promise for delivering higher returns and have limited downside risk. If you are looking for an extremely cheap AI stock that is also a major beneficiary of Trump tariffs and onshoring, see our free report on the best short-term AI stock. READ NEXT: and . Disclosure: None. Sign in to access your portfolio
Yahoo
2 days ago
- Yahoo
2 AI Growth Stocks That Could Help Set You Up for Life
Credo provides a lot of key components for upgrading AI-driven data centers. Arm's AI-optimized designs and new first-party chipmaking business could drive its long-term growth. Neither of these stocks is cheap, but they both deserve their premium valuations. 10 stocks we like better than Credo Technology Group › The artificial intelligence (AI) market has grown like a weed over the past decade. That rapid expansion -- which was fueled by more sophisticated cloud computing services, large language models, and generative AI applications -- lit a blazing fire under some high-growth tech stocks. The most obvious winners are Nvidia, the world's top producer of discrete graphics processing units (GPUs) for processing AI tasks; and Microsoft, which acquired a big stake in OpenAI and integrated the start-up's AI tools into its own services. But there are still plenty of other under-the-radar AI growth plays that might have more upside potential. Let's look at two of them: Credo Technology (NASDAQ: CRDO) and Arm Holdings (NASDAQ: ARM). Credo, which went public in 2022, sells a wide range of high-speed connectivity solutions for the data center, cloud, and AI markets. Its core products include data transfer chips, digital signal processors, line card components, and active electric cables for data centers. From fiscal 2022 to fiscal 2025 (which ended this May), Credo's revenue grew at a compound annual growth rate (CAGR) of 60%. It also turned profitable for the first time in fiscal 2025. Credo attributed that growth to the rapid expansion of the cloud and AI markets, which drove its hyperscale customers to aggressively upgrade their data center infrastructure. Its biggest customer -- widely believed to be Microsoft -- accounted for 39% of its revenue in fiscal 2024. That customer concentration isn't ideal, but it also isn't surprising considering how much Microsoft is prioritizing the expansion of its cloud and AI ecosystems. Its other major customers include Amazon and Tesla. From fiscal 2025 to fiscal 2027, analysts expect Credo's revenue to rise at a CAGR of 47% as its earnings per share (EPS) increase at a CAGR of 113%. That rapid growth could be driven by the continued expansion of the AI market, and a shift toward higher-speed ethernet connections that will spur demand for its new optical modules. There's also rising demand for its "chiplet" designs, which are more modular, customizable, and scalable than monolithic system on chips (SoCs), which merge together multiple chips on a single die. It isn't cheap at 64 times this year's earnings, but it could have plenty of room to run over the next few decades. Arm is a U.K. chip designer which was acquired by Japan's SoftBank in 2016 and spun off again in a second IPO in 2023. It develops power-efficient CPUs that consume less power than the x86 CPUs produced by Intel and AMD. That makes Arm's chips well-suited for smartphones, tablets, Internet of Things (IoT) gadgets, connected vehicles, and even some notebook computers and servers. Its chip designs are now installed in approximately 99% of the world's smartphones, and most of its growth over the past few years has been fueled by its AI-optimized Armv9 designs. Arm's revenue rose 24% in fiscal 2025 (which ended this March), and analysts expect that figure to grow at a CAGR of 21% over the next three years. Its EPS, which surged 159% in fiscal 2025, is expected to grow at a CAGR of 41% through fiscal 2028. Arm originally only generated its revenue by licensing its designs to chipmakers like Qualcomm, MediaTek, and Apple instead of producing its own chips. But earlier this year, it announced that it would start developing its own first-party chips and outsource its production to Taiwan Semiconductor Manufacturing. That surprising move would boost Arm's operating expenses and turn it into a direct competitor for some of its top clients. But it could also undercut other Arm-based chips because it doesn't need to pay any royalties or licensing fees for its own designs. Its first-party brand recognition could also make it a more appealing option than third-party Arm-based chips for OEMs. Arm's stock certainly isn't cheap at 113 times this year's earnings, but it could be a great long-term play on the market's growing demand for more power-efficient AI chips. Before you buy stock in Credo Technology Group, consider this: The Motley Fool Stock Advisor analyst team just identified what they believe are the for investors to buy now… and Credo Technology Group wasn't one of them. The 10 stocks that made the cut could produce monster returns in the coming years. Consider when Netflix made this list on December 17, 2004... if you invested $1,000 at the time of our recommendation, you'd have $656,825!* Or when Nvidia made this list on April 15, 2005... if you invested $1,000 at the time of our recommendation, you'd have $865,550!* Now, it's worth noting Stock Advisor's total average return is 994% — a market-crushing outperformance compared to 172% for the S&P 500. Don't miss out on the latest top 10 list, available when you join . See the 10 stocks » *Stock Advisor returns as of June 2, 2025 John Mackey, former CEO of Whole Foods Market, an Amazon subsidiary, is a member of The Motley Fool's board of directors. Leo Sun has positions in Amazon and Apple. The Motley Fool has positions in and recommends Advanced Micro Devices, Amazon, Apple, Intel, Microsoft, Nvidia, Qualcomm, Taiwan Semiconductor Manufacturing, and Tesla. The Motley Fool recommends the following options: long January 2026 $395 calls on Microsoft, short August 2025 $24 calls on Intel, and short January 2026 $405 calls on Microsoft. The Motley Fool has a disclosure policy. 2 AI Growth Stocks That Could Help Set You Up for Life was originally published by The Motley Fool Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
